NASDAQ:PCVX

Vaxcyte Q3 2026 Earnings Results & Report

Vaxcyte logo
$55.39 -2.97 (-5.09%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$55.71 +0.32 (+0.58%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$1.99 versus the -$2.11 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Vaxcyte EPS Results

Actual EPS
-$1.99
Consensus EPS
-$2.11
Beat/Miss
Beat by +$0.12
One Year Ago EPS
-$1.56
EPS Beat Rate
3 of last 8 quarters

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Q3 2026 Earnings FAQ

Vaxcyte (NASDAQ:PCVX) reported earnings of -$1.99 per share for Q3 2026, beating the consensus estimate of -$2.11. The report was announced on Wednesday, November 4, 2026.

Vaxcyte Earnings Headlines

TD Cowen Remains a Buy on Vaxcyte (PCVX)
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Has Average Price Target of $110.50
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX) is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response.

The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.

Founded as SutroVax, the company adopted the Vaxcyte name in 2020. It is headquartered in San Carlos, California, and is led by co-founder and Chief Executive Officer Grant Pickering.

View Vaxcyte Profile